Involvement of Rac in fenretinide-induced apoptosis

Cancer Research

Volumn 68, Issue 11, 2008, Pages 4416-4423

  Kadara, Humam ^a   Tahara, Eiji ^a   Kim, Hyun Jung ^a   Lotan, Dafna ^a   Myers, Jeffrey ^a   Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; GUANOSINE TRIPHOSPHATASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NSC 23766; PROTEIN INHIBITOR; RAC PROTEIN; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; GENE EXPRESSION; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LUNG CANCER; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; RNA INTERFERENCE; UTERINE CERVIX CANCER; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

AMINOQUINOLINES; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; FENRETINIDE; HEAD AND NECK NEOPLASMS; HUMANS; PYRIMIDINES; RAC GTP-BINDING PROTEINS; REACTIVE OXYGEN SPECIES;

EID: 49249097594     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0031     Document Type: Article

References (47)

1. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Hail N, Jr., Kim HJ, Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006;11:1677-94.
4. Sun SY, Hail N, Jr., Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004;96:662-72.
5. Moon RC, Thompson HJ, Becci PJ, et al. N-(4-Hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979;39:1339-46.
6. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979;38:2528-34.
7. Malone W, Perloff M, Crowell J, Sigman CHigley H. Fenretinide: a prototype cancer prevention drug. Expert Opin Investig Drugs 2003;12:1829-42.
8. Chiesa F, Tradati N, Grigolato R, et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005;115:625-9.
9. Lippman SM, Lee JJ, Martin JW, et al. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 2006;12:3109-14.
10. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006;17:1065-71.
11. Bast RC, Jr., Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007;174:91-100.
12. Sun SY, Li W, Yue P, et al. Mediation of N-(4-hydoxyphenyl) retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999;59:2493-8.
13. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl) -retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-46.
14. Hail N, Jr., Lotan R. Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Cancer Epidemiol Biomarkers Prev 2000;9: 1293-301.
15. Lovat PE, Oliverio S, Ranalli M, et al. GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res 2002;62:5158-67.
16. Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther 2002;1:1009-17.
17. Asumendi A, Morales MC, Alvarez A, Arechaga J, Perez-Yarza G. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl) retinamide-induced apoptosis. Br J Cancer 2002;86:1951-6.
18. Delia D, Aiello A, Meroni L, et al. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997;18:943-8.
19. Hail N, Jr., Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl) retinamide. J Biol Chem 2001;276:45614-21.
20. Chen YR, Zhou G, Tan TH. c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl) retinamide. Mol Pharmacol 1999;56:1271-9.
21. Kim HJ, Chakravarti N, Oridate N, et al. N-(4-Hydroxyphenyl) retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 2006;25:2785-94.
22. Osone S, Hosoi H, Kuwahara Y, et al. Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells. Int J Cancer 2004;112:219-24.
23. Kadara H, Lacroix L, Lotan D, Lotan R. Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-hydroxyphenyl)retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells. Cancer Biol Ther 2007;6:705-11.
24. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004;4:181-9.
25. Babior BM. NADPH oxidase: an update. Blood 1999;93:1464-76.
26. De Leo FR, Ulman KV, Davis AR, Jutila KL, Quinn MT. Assembly of the human neutrophil NADPH oxidase involves binding of p67phox and flavocytochrome b to a common functional domain in p47phox. J Biol Chem 1996;271:17013-20.
27. Hwang JJ, Choi SY, Koh JY. The role of NADPH oxidase, neuronal nitric oxide synthase and poly(ADP ribose) polymerase in oxidative neuronal death induced in cortical cultures by brain-derived neurotrophic factor and neurotrophin-4/5. J Neurochem 2002;82:894-902.
28. Lee TK, Poon RT, Yuen AP, et al. Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression. Clin Cancer Res 2006;12:5082-9.
29. Lee YS, Kang YS, Lee SH, Kim JA. Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ 2000;7:925-32.
30. Tammariello SP, Quinn MT, Estus S. NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons. J Neurosci 2000;20:RC53.
31. Suzuki S, Higuchi M, Proske RJ, et al. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene 1999;18:6380-7.
32. Sun SY, Yue P, Dawson MI, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997;57:4931-9.
33. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 2004;101:7618-23.
34. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006;6:459-71.
35. Chan AY, Coniglio SJ, Chuang YY, et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 2005;24:7821-9.
36. Rassool FV, Gaymes TJ, Omidvar N, et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res 2007;67:8762-71.
37. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006;25:695-705.
38. Cheng G, Diebold BA, Hughes Y, Lambeth JD. Nox1-dependent reactive oxygen generation is regulated by Rac1. J Biol Chem 2006;281:17718-26.
39. Kawazoe N, Watabe M, Masuda Y, Nakajo S, Nakaya K. Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 1999;18:2413-21.
40. Kim S, Moon A. Capsaicin-induced apoptosis of H-ras-transformed human breast epithelial cells is Rac-dependent via ROS generation. Arch Pharm Res 2004;27:845-9.
41. Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995;81:1147-57.
42. Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006;51:363-8.
43. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-8.
44. Schimmel M, Bauer G. Proapoptotic and redox state-related signaling of reactive oxygen species generated by transformed fibroblasts. Oncogene 2002;21:5886-96.
45. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002;3:420-5.
46. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 2006;10:241-52.
47. Ferraro D, Corso S, Fasano E, et al. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 2006;25:3689-98.